Engwerda Christian R, Matlashewski Greg
QIMR Berghofer, Brisbane, Australia
Department of Microbiology and Immunology, McGill University, Montreal, Canada.
Trans R Soc Trop Med Hyg. 2015 Jul;109(7):423-4. doi: 10.1093/trstmh/trv039. Epub 2015 Jun 4.
A visceral leishmaniasis (VL) elimination target set for the Indian subcontinent in 2005 is being met in many endemic areas without a vaccine. This begs a question: is a VL vaccine needed if elimination targets can be met with current control programs? Here, we argue that a vaccine will be critical if the success of recent VL control efforts are to be sustained. However, not only do we require a safe and effective vaccine, but we also need to know how this should be used for maximum impact. In particular, identifying appropriate target populations to vaccinate will be crucial.
2005年为印度次大陆设定的内脏利什曼病（VL）消除目标，在许多流行地区在没有疫苗的情况下正在实现。这就引出了一个问题：如果通过当前的控制项目能够实现消除目标，是否还需要VL疫苗？在此，我们认为，如果要维持近期VL控制工作的成功，疫苗将至关重要。然而，我们不仅需要一种安全有效的疫苗，还需要知道如何使用它才能产生最大影响。特别是，确定合适的接种目标人群将至关重要。
